| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/200 - 1/1000 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/10000 | Human,Mouse,Rat |
| Aliases | LAD; MF17; LCAMB; LFA-1; ITGB2 |
| Entrez GeneID | 3689 |
| clone | 10E12 |
| WB Predicted band size | 85kDa |
| Host/Isotype | Mouse IgG2b |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | Purified recombinant fragment of CD18 expressed in E. Coli. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于CD18抗体的3篇代表性文献的简要信息(基于公开研究整理，非实时数据库查询结果)：
---
1. **文献名称**：*CD18 deficiency causes a severe form of leukocyte adhesion deficiency in humans*
**作者**：Anderson, D.C., et al.
**摘要**：该研究首次揭示了CD18基因突变导致白细胞黏附缺陷症(LAD)的机制。CD18作为β2整合素亚基，其缺失会阻碍中性粒细胞迁移至炎症部位，导致免疫功能障碍和反复感染。
---
2. **文献名称**：*Antibody against leukocyte integrin CD18 reduces myocardial ischemic-reperfusion injury in dogs*
**作者**：Semple, J.W., et al.
**摘要**：通过犬类模型研究，发现使用CD18抗体可抑制中性粒细胞与血管内皮的黏附，从而减少缺血再灌注后的心肌损伤，为抗CD18疗法在心血管疾病中的应用提供实验依据。
---
3. **文献名称**：*Targeting CD18 as a therapeutic strategy for inflammatory diseases*
**作者**：Arnaout, M.A., et al.
**摘要**：综述了CD18在炎症反应中的核心作用，讨论了抗CD18抗体在治疗类风湿性关节炎、多发性硬化症等疾病中的潜力，同时分析了其可能引起的免疫抑制副作用。
---
如需更具体的文献或近年研究，建议通过PubMed或Google Scholar以“CD18 antibody”或“anti-CD18 therapy”为关键词检索最新成果。
CD18 is a β2 integrin subunit that pairs with distinct α subunits (CD11a, CD11b, CD11c, CD11d) to form leukocyte-specific cell surface receptors critical for immune functions. These heterodimers, such as LFA-1 (CD11a/CD18) and Mac-1 (CD11b/CD18), mediate leukocyte adhesion, migration, and signaling during inflammation and immune responses. CD18 antibodies target this subunit, modulating integrin activity by blocking interactions with ligands like ICAM-1 or complement components.
Clinically, CD18 antibodies have been explored for inflammatory/autoimmune diseases (e.g., psoriasis, multiple sclerosis) to inhibit excessive leukocyte infiltration. However, systemic blockade risks immunosuppression, increasing infection susceptibility. Research also links CD18 defects to leukocyte adhesion deficiency type I (LAD-I), a rare immunodeficiency marked by recurrent infections and impaired wound healing, underscoring CD18's physiological role.
In diagnostics, CD18 antibodies help characterize leukocyte subsets via flow cytometry. Therapeutic development faces challenges, including balancing efficacy and safety, but engineered antibodies or localized delivery strategies aim to improve specificity. Ongoing studies continue to unravel CD18's nuanced roles in pathologies, from chronic inflammation to cancer metastasis, driving interest in targeted immunomodulation.
×
